AI Drug Repurposing Market

What is the AI Drug Repurposing Market forecast to be worth by 2036?

USD 1.5 billion in 2026 to USD 8.8 billion by 2036 at 19.4% CAGR.

• The AI drug repurposing market crossed a valuation of USD 1.3 billion in 2025.
• Demand is projected to increase from USD 1.5 billion in 2026 to USD 8.8 billion by 2036.
• The market is forecast to record 19.4% CAGR from 2026 to 2036 as validation-ready AI workflows move into portfolio planning.

What are the defining numbers behind AI Drug Repurposing Market growth?

USD 7.3 billion absolute opportunity by 2036.

• Demand Drivers in the Market
  • Approved and investigational compound libraries give sponsors a starting point before new laboratory work is approved.
  • Disease networks help teams compare known drug behavior with unmet clinical needs before they spend on early experiments.
  • Portfolio teams use ranked evidence to decide whether a candidate deserves assays, licensing review or regulatory discussion.
• Key Segments Analyzed
  • By Drug Type: Small Molecule Drugs are expected to hold 39.0% share in 2026 due to clear structures and reusable dosing histories.
  • By Application: Oncology is projected to account for 32.0% share in 2026. Biomarker-led care creates clear indication-matching use cases.
  • By End User: Pharmaceutical Companies are anticipated to capture 41.0% share in 2026. They control compounds and development budgets.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “AI drug repurposing platforms must show that ranked candidates can withstand scientific review before they move into licensing or validation. Commercial adoption is expected to depend on transparent model output, clear data lineage and strong links to assay or clinical evidence rather than prediction accuracy alone.”
• Strategic Implications
  • Pharmaceutical teams should connect AI ranking with wet-lab confirmation before licensing decisions accelerate.
  • Platform vendors can explain data lineage in plain terms so biology teams understand candidate ranking.
  • Investors should review whether licensing terms cover indication ownership and development handoff.

The USA leads with a 20.2% CAGR, supported by enterprise platform purchases. Japan follows at 19.6% through pharmaceutical partnerships, while Germany reaches 19.2% through governed clinical data. The UK, Canada, South Korea and Australia grow through research networks, federated programs and biotechnology validation activities.

How does the AI Drug Repurposing Market break down by segment?

Small Molecule Drugs are expected to lead Drug Type at 39.0% share in 2026. Oncology is projected to lead Application at 32.0% share in 2026.

Why does Small Molecule Drugs lead Drug Type?

Small Molecule Drugs are projected to account for 39.0% share in 2026.

Small molecules offer the broadest inventory of approved and investigational compounds for repurposing. Their known chemical structures, dosing histories and safety records make them easier to compare across new disease targets.

Why does Oncology lead Application?

Oncology is expected to account for 32.0% share in 2026.

Oncology provides strong demand because molecular profiling and biomarker-defined patient groups create clear indication-matching opportunities. Solid tumors and hematological malignancies generate large evidence sets that AI platforms can compare with known drug activity.

Why do Pharmaceutical Companies lead End User?

Pharmaceutical Companies are anticipated to account for 41.0% share in 2026.

Pharmaceutical companies control compound libraries, clinical records and development budgets, giving them the strongest ability to move repurposed candidates into assays or trials. Large pharmaceutical companies can connect AI platforms with internal research teams.

What is accelerating AI Drug Repurposing Market adoption, and what is holding it back?

Demand is expected to rise as companies reuse known drugs and improve candidate selection. Growth may be limited by validation needs, data restrictions and regulatory concerns.

Drivers Impact Analysis

• Known-compound reuse: Sponsors are expected to value AI programs that make prior toxicology and exposure records easier to reuse.
• Evidence graph matching: Disease maps are expected to help teams compare drug behavior with disease biology before lab work begins.
• Portfolio productivity pressure: R&D leaders are likely to favor tools that filter weak candidates before new experiments are approved.

Opportunity Impact Analysis

• Privacy-preserving collaboration: Federated data models are expected to help institutions learn from sensitive datasets without raw-data transfer.
• Multimodal evidence scoring: Platforms that combine biology with text and clinical signals are likely to gain more proof during buyer review.
• Rare-disease partnerships: Developers may find stronger openings where small populations make conventional discovery paths less efficient.

Restraints Impact Analysis

• Validation and regulatory credibility: Predictions must be traceable enough for scientific review before buyers treat them as development evidence.
• Data-rights restrictions: Sensitive clinical records and proprietary compound files limit how quickly teams can pool data for model training.
• Prospective evidence cost: Sponsors still need assays or clinical work before a ranked candidate becomes a development program.

Which countries are scaling AI Drug Repurposing Market fastest?

The USA leads the country comparison, followed closely by Japan and Germany. The UK remains near this group, while Canada, South Korea and Australia follow. With a 2.4-point spread, providers need country-specific evidence aligned with data rules and partnership models.

• The USA leads since large pharmaceutical buyers can connect AI candidate ranking with internal assay teams and regulatory review. Japan remains close to the lead through domestic pharmaceutical partnerships and translational programs that support proof-of-concept work.
• Germany is shaped by governed clinical-data access, privacy review and reproducibility expectations in research consortia. The UK benefits from NHS research settings and university expertise. Specialist AI developers work near pharmaceutical buyers.
• Canada builds demand through university hospitals and AI institutes. Open-science networks support collaborative repurposing work. South Korea follows a partnership-led route where federated discovery programs and hospital collaboration support local model development.
• Australia records a measured position. Research hospitals and biotechnology groups create selective demand for repurposing workflows.

Comparable CAGRs can still produce different adoption paths. Commercial readiness depends on evidence standards, data access and validation handoff.

The full report provides country-level CAGR analysis across the profiled regions.

What supports USA adoption?

20.2% CAGR, supported by enterprise platform purchasing and regulatory review discipline.

The USA reflects a market where pharmaceutical teams use enterprise platform agreements, sponsored research and asset-level licensing. Buyers connect computational work to assay groups before development spend expands.

How is Japan scaling demand?

19.6% CAGR, driven by pharmaceutical partnerships and translational research programs.

Japan’s growth is tied to domestic pharmaceutical partnerships, university collaboration and translational activity. Buyers test platform credibility through controlled research programs before larger development rights are negotiated.

What shapes Germany’s outlook through 2036?

19.2% CAGR, backed by governed clinical-data access and reproducibility review.

Germany’s growth reflects strong attention to privacy-protected data use. Suppliers must show reproducible workflows and controlled access before AI output supports repurposing decisions.

How does the UK develop adoption?

18.9% CAGR, supported by specialist AI developers and NHS research routes.

The UK benefits from pharmaceutical companies and NHS research settings. Universities and specialist AI developers support proof-of-concept work before wider platform use.

What supports Canada’s growth?

18.5% CAGR, led by university hospitals and AI institutes.

Canada often assembles repurposing programs through public research networks and hospital AI expertise. Demand develops where teams connect disease biology with validation partners.

How is South Korea building demand?

18.1% CAGR, shaped by federated discovery programs and hospital collaboration.

South Korea’s route depends on partnerships among pharmaceutical companies, hospitals and research institutes. Federated models appeal where participants need shared learning without centralizing sensitive data.

What supports Australia’s position?

17.8% CAGR, supported by research hospitals and biotechnology-led validation work.

Australia shows selective adoption through research hospitals and biotechnology groups. Buyers compare platform output with available clinical expertise before advancing candidates.

Who leads the AI Drug Repurposing Market?

BenevolentAI and Healx show direct relevance through indication intelligence. BioXcel Therapeutics add disease-to-drug matching experience.

Insilico Medicine bring multimodal discovery workflows. Recursion Pharmaceuticals and Valo Health add larger data-driven discovery platforms. Schrödinger and Numerion Labs strengthen screening and computational chemistry. The comparison fits Fact.MR's Artificial Intelligence in Drug Discovery Market.

From 2026 to 2036, competition is expected to depend on transparent model output and evidence transfer. Buyers compare whether ranked candidates can move into assays or clinical planning without losing data rights. Provider credibility improves when model output can be explained to scientists and licensing teams. A ranked list has limited value unless the next action is clear.

Which companies are the key providers?

Key companies include BenevolentAI; Insilico Medicine; Recursion Pharmaceuticals; Schrödinger; Numerion Labs; Healx; BioXcel Therapeutics; Valo Health.

• BenevolentAI
• Insilico Medicine
• Recursion Pharmaceuticals
• Schrödinger
• Numerion Labs
• Healx
• BioXcel Therapeutics
• Valo Health

Bibliography

• National Center for Advancing Translational Sciences. (2024, February 29). Repurposed drug helps cells clear defective proteins, reveals route to new therapies. National Institutes of Health.
• European Medicines Agency. (2024, September 30). Reflection paper on the use of artificial intelligence in the medicinal product lifecycle.
• U.S. Food and Drug Administration, & European Medicines Agency. (2026, January 14). Guiding principles of good AI practice in drug development.

This Report Answers

• The report provides intelligence on Drug Type and Application choices that shape AI drug repurposing workflows.
• Segment analysis covers Small Molecule Drugs and Oncology as the leading 2026 share positions.
• Country outlook evaluates the USA and Japan alongside Germany and the UK. Canada, South Korea and Australia complete the comparison.
• Competitive analysis profiles the ten listed providers without assigning company share.
• Technology assessment covers Machine Learning and its role in evidence ranking and validation workflows.

What does the AI Drug Repurposing Market cover?

AI-enabled platforms identify and rank new therapeutic indications for known drugs before validation work begins.

The market covers platform access and subscriptions. It includes research services, licensing support and custom analytical work tied to new indication discovery. Downstream finished-drug sales and off-label clinical revenue are excluded. Scope discipline protects the boundary of this market. Revenue is counted only when the service helps identify or transfer a new use for a known drug.

What is included in the scope?

The scope includes Drug Type and Application alongside End User, Distribution Channel and Technology.

Coverage spans Small Molecule Drugs and Oncology. Pharmaceutical Companies, Direct Licensing and Machine Learning are included. Strategic licensing and technology transfer revenue are counted when they support repurposing programs.

What is excluded from the scope?

Finished-drug sales and unrelated discovery services remain outside the scope of this market.

The scope excludes standard contract research that is not tied to AI-enabled repurposing. General AI consulting is excluded unless it identifies or validates a new indication for a known drug.

How Was the Analysis Built?

The analysis draws on 120+ sources; 35+ company portfolios; 25+ countries; and more than 20 industry interviews.

• Primary Research: Primary research includes discussions with AI platform developers and pharmaceutical R&D teams. Biotechnology companies, licensing professionals and CROs add buying context. Research hospitals and regulatory specialists clarify validation expectations.
• Desk Research: Desk research covers regulator guidance and public-funding records. Peer-reviewed literature, company filings and official releases listed in the bibliography are reviewed.
• Market Sizing and Forecasting: Estimates combine platform access and direct licensing activity. Strategic collaborations, contract research and cloud AI services are included when they support repurposing revenue.
• Data Validation and Update Cycle: Values and shares are reconciled across sections. Updates review launches and financing. Partnerships and approvals are checked during refresh cycles.